NCT04606329View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3)

PHASE3CompletedINTERVENTIONAL

Enrollment

109

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions

Breast Diseases

Interventions

DRUG

LuminoMark inj.(Conc. for fluorescence)

Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.

DRUG

Charcotrace Inj.

Injection Charcotrace Inj. about 0.3\~1mL once in this study.

Trial Locations (1)

06351

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Hanlim Pharm. Co., Ltd.

INDUSTRY

NCT04606329 - To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions(Phase 3) | Biotech Hunter | Biotech Hunter